Lukas K. Van Vugt
Rotterdam, ZH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
A Real-World Clinical Evaluation of Ganciclovir Exposure and Cytomegalovirus Viremia Outcomes After Adult Kidney Transplantation.
Journal: Therapeutic drug monitoring
Published: March 16, 2025
Alemtuzumab Exposure and T Lymphocyte Depletion: A Population Pharmacokinetic-Pharmacodynamic Model of Alemtuzumab Induction Therapy for Kidney Transplantation.
Journal: Clinical pharmacology and therapeutics
Published: February 16, 2025
Multicenter, Real-World Clinical Evaluation of Alemtuzumab and Anti-Thymocyte Globulin for Severe Acute T Cell-Mediated Kidney Transplant Rejection.
Journal: Clinical transplantation
Published: August 30, 2024
Recurrent treatment of refractory acute cellular rejection with alemtuzumab after lung transplantation.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
Published: March 29, 2024
Challenges for the improvement of valganciclovir prophylaxis in solid organ transplantation and the possible role of therapeutic drug monitoring in adults.
Journal: British journal of clinical pharmacology
Published: March 08, 2024
A Decade of Experience With Alemtuzumab Therapy for Severe or Glucocorticoid-Resistant Kidney Transplant Rejection.
Journal: Transplant international : official journal of the European Society for Organ Transplantation
Published: July 27, 2023
Investigational drugs for the treatment of kidney transplant rejection.
Journal: Expert opinion on investigational drugs
Published: September 29, 2022
Personalized anti-rejection therapy with alemtuzumab for kidney transplant recipients.
Journal: Pharmacogenomics
Published: June 28, 2022
Showing 1-8 of 8
Last Updated: 09/26/2026